Publication Name	World Journal of Stem Cells
Manuscript ID	7382
Country	Spain

Received	2013-11-15 16:24
Peer-Review Started	2013-11-18 09:14
To Make the First Decision	2014-02-13 16:28
Return for Revision	2014-02-20 19:36
Revised	2014-03-24 23:50
Second Decision	2014-06-11 13:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-06-11 13:35
Articles in Press	2014-06-11 13:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-18 11:33
Publish the Manuscript Online	2014-07-19 21:17

ISSN	1948-0210 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics
Manuscript Source	Invited Manuscript
All Author List	Antonio Garcia-Gomez, Fermin Sanchez-Guijo, M Consuelo del Cañizo, Jesus F San Miguel and Mercedes Garayoa
Funding Agency and Grant Number	Funding Agency Grant Number Spanish Ministry of Economía y Competitividad-Instituto de Salud Carlos III PI12/02591 European Funds for Regional Development Spanish Health Thematic Networks of Cooperative Research in Cancer RTICC RD12/0036/0058 Cellular Therapy TerCel RD12/0019/0001(group 8) Network of Centers for Regenerative Medicine and Cellular Therapy from Castilla y León Spanish Society of Hematology and Hemotherapy (to Garcia-Gomez A)
Corresponding Author	Mercedes Garayoa, PhD, Cancer Research Center, IBMCC (University of Salamanca-CSIC), Campus Miguel de Unamuno, Avda. Coimbra s/n, 37007 Salamanca, Spain. mgarayoa@usal.es
Key Words	Mesenchymal stromal cells; Multiple myeloma; Osteolytic lesions; Myeloma bone disease; Bone-directed therapy; Bone-anabolic drugs
Core Tip	In multiple myeloma, bone marrow mesenchymal stromal cells (MSCs) primarily contribute to associated osteolytic lesions because of their defective differentiation to mature osteoblasts. Importantly, these MSCs also contribute to myeloma bone disease by enhancing osteoclast formation and activity through various mechanisms (i.e., increasing the receptor activator of nuclear factor-kB ligand/osteoprotegerin ratio, augmenting activin A secretion, uncoupling ephrinB2-EphB4 signaling and because of heightened production of Wnt5a). In addition, we overview signaling pathways involved in the osteogenic differentiation of MSCs or osteoblast activity and comment on the reported activity of bone-anabolic agents (preclinical or clinical stage) to restore bone homeostasis in myeloma patients.
Publish Date	2014-07-19 21:17
Citation	Garcia-Gomez A, Sanchez-Guijo F, del Cañizo MC, San Miguel JF, Garayoa M. Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells 2014; 6(3): 322-343
URL	http://www.wjgnet.com/1948-0210/full/v6/i3/322.htm
DOI	http://dx.doi.org/10.4252/wjsc.v6.i3.322

Full Article (PDF)	WJSC-6-322.pdf
Full Article (Word)	WJSC-6-322.doc
Manuscript File	7382-Review.docx
Answering Reviewers	7382-Answering reviewers.pdf
Copyright License Agreement	7382-Copyright assignment.pdf
Peer-review Report	7382-Peer review(s).pdf
Scientific Misconduct Check	7382-CrossCheck.jpg
Scientific Editor Work List	7382-Scientific editor work list.pdf